Trial · NCT05173896
Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial
NCT05173896, Phase 2, Active not recruiting, Christina Kruuse
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial. Trials, record NCT05173896. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05173896
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial
- NCT number
- NCT05173896
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Christina Kruuse
- Conditions
- Cerebral Small Vessel Diseases, Stroke, Ischemic
- Interventions
- Tadalafil 20 MG, Placebo
- First posted
- 2021-12-30
- Last updated
- 2024-12-09
- Other registries' IDs
- eudract:2020-002329-27
Source ClinicalTrials.gov
Registered outcomes38
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility of treatment defined as proportion of participants achieving full target dose of tadalafil/placebo. | From baseline to three months. | Number of participants achieving full target dose of tadalafil/placebo by end of three months trial period. Outcome will be assessed by a structured questionnaire with tablet count. |
| Secondary | MRI - Cerebral Blood Flow | From baseline to three months. | Change in cerebral blood flow measured with arterial spin labeling (ASL) during a sensory hand stimulus. |
| Secondary | MRI - Neurovascular reactivity and perfusion | From baseline to three months. | Change in neurovascular reactivity, coupling, and cerebral blood flow/perfusion measured with BOLD/ASL during a visual stimulation with and without a carbon dioxide vascular challenge. |
| Secondary | MRI - Neurovascular reactivity | From baseline to three months. | Change in neurovascular reactivity measured with blood-oxygen-level dependent (BOLD) during a sensory hand stimulus. |
| Secondary | MRI - Blood Brain Barrier | From baseline to three months. | Change in blood brain barrier measured with diffusion-prepared (DP)-ASL MRI. |
| Secondary | MRI - STRIVE criteria | From baseline to three months. | Relative changes (%) in STRIVE assessment, including new strokes, white matter hyperintensity, cerebral microbleeds, enlarged perivascular space, atrophy, and lacunes. |
| Secondary | Montreal Cognitive Assessment | From baseline to three months. | Change in Montreal Cognitive Assessment (MoCA) score. Score range 0-30. Higher scores mean a better outcome. |
| Secondary | Symbol Digit Modalities Test | From baseline to three months. | Change in Symbol Digit Modalities Test (SDMT) score. Score range 0-110. Higher scores mean a better outcome. |
| Secondary | Dementia Assessment by Rapid Test | From baseline to three months. | Change in Dementia Assessment by Rapid Test - DART score. Score range 0-50. Higher scores mean a better outcome. |
| Secondary | Trail Making Test A | From baseline to three months. | Change in time to perform Trail Making Test A. Quicker time means a better outcome. |
1 to 10 of 38Source ClinicalTrials.gov
See all 38 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests8
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| One-Touch Tower Planning | Secondary outcome | ConductCognition |
| Paired Associate Learning | Secondary outcome | ConductCognition |
| Rapid Visual Information Processing | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Tower Planning | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05173896
GET https://conductscience.org/api/trials/v1/NCT05173896/registered?page=2